Scientists discover way to protect against death following plague infection Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection.In fact, a signature of the plague is the lack of an inflammatory response.
Now, scientists have discovered a...
Mimic molecules to protect against plague , 7:25 PM EST Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection.In fact, a signature of the plague is the lack of an inflammatory response.
Now, scientists have...
Peregrine Pharmaceuticals awarded DTRA contract worth up to $44.4 million to develop Bavituximab for Viral Hem TUSTIN, Calif.- Peregrine Pharmaceuticals, Inc.
(NASDAQ:PPHM) , a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced it has...
Peregrine wins $44.4 million DTRA contract The initial contract was awarded through the transformational medical technologies initiative of the US Department of Defense's Defense Threat Reduction Agency (DTRA).Under the terms of the contact, DTRA funds are available to cover...
Trauma Nursing, From Resuscitation Through Rehabilitation, 4th Edition Using the unique cycles of trauma framework, the 4th edition of this classic and highly acclaimed resource is thoroughly updated to bring you comprehensive coverage of cutting-edge research findings and current issues, trends, and...
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hem TUSTIN, Calif.Bavituximab is Peregrine's lead anti-phosphatidylserine (anti-PS) monoclonal antibody and is currently in clinical trials for the treatment of HCV infections and cancer.
In preclinical animal models, bavituximab has...
A New Farm Bill, Research Structure at USDA The significant challenges facing national food, fiber, and bioenergy systems call for a robust agricultural research system, whether for addressing food safety, security, and availability; thwarting disruptions to food supplies; or managing...
NIAID announces grants to stimulate food allergy research Twelve investigators have received grants totaling $5 million over two years to lead high-impact, innovative studies of food allergy, a significant public health concern.This program, called Exploratory Investigations in Food Allergy, is...
Aethlon Medical Announces Second HIV/AIDS Treatment Site - Aethlon Medical, Inc.(OTCBB:AEMD) announced today that it has added a second HIV/AIDS clinical study location at the Bhvani Hospital in Bihar, India.
Aethlon previously disclosed plans to initiate the 'first-in-man' clinical study of...
Aethlon Medical Announces Second HIV/AIDS Treatment Site Aethlon Medical Inc (AEMD) Stock Quote, Chart, News, Add to Watchlist Aethlon Medical, Inc.AEMD announced today that it has added a second HIV/AIDS clinical study location at the Bhvani Hospital in Bihar, India.
Aethlon previously...
Aethlon Medical Announces Second HIV/AIDS Treatment Site Company Website: http://www.aethlonmedical.com SAN DIEGO -- (Business Wire) Aethlon Medical, Inc.(OTCBB:AEMD) announced today that it has added a second HIV/AIDS clinical study location at the Bhvani Hospital in Bihar, India.
Aethlon...
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hem - Five-Year Defense Threat Reduction Agency Contract Will Support Development of Bavituximab and Fully Human Equivalent as Potential Broad-Spectrum Anti-Viral Agents - TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine...
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hem - Five-Year Defense Threat Reduction Agency Contract Will Support Development of Bavituximab and Fully Human Equivalent as Potential Broad-Spectrum Anti-Viral Agents - TUSTIN, Calif., July 01, 2008 /PRNewswire-FirstCall/ -- Peregrine...
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hem TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection,...
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hem TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection,...
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hem TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection,...
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hem TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.(Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection,...
Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million Bavituximab is Peregrine's lead anti-phosphatidylserine (anti-PS) monoclonal antibody and is currently in clinical trials for the treatment of HCV infections and cancer.In preclinical animal models, bavituximab has demonstrated...
Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis Investment Firm, Allied Minds, Establishes New Company to Commercialize Novel Technology from UC Davis BOSTON, June 30 /PRNewswire/ -- Allied Minds, a pre-seed investment firm specializing in early stage university business ventures, has...
FDA report shows limits of canneries oversightLast July, Food and Drug Administration officials issued a rare Last July, Food and Drug Administration officials issued a rare warning to U.S.consumers: Botulism toxin was suspected in hot dog chili made by Castleberry's Food.
The botulism outbreak, which would sicken eight people and lead to a...
New type of ultraviolet diode could lead to compact anthrax detector A new class of ultraviolet photodiode could make possible a compact, reliable and cost-effective sensor to detect anthrax and other bioterrorism agents in the air.Research conducted at the Georgia Institute of Technology, shows that...
DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory, Phase 3 Clini -- DOR BioPharma, Inc.(DORB) ('DOR' or the 'Company'), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against...
DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory, Phase 3 Clini (Marketwire Via Acquire Media NewsEdge) EWING, NJ, June 30 / MARKET WIRE/ -- DOR BioPharma, Inc.(OTCBB: DORB) ('DOR' or the 'Company'), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of...
DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory, Phase 3 Clini -- DOR BioPharma, Inc.(OTC BB:DORB.OB - News) ('DOR' or the 'Company'), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and...
DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory, Phase 3 Clini EWING, NJ, June 30 / MARKET WIRE/ -- DOR BioPharma, Inc.(OTCBB: DORB) ('DOR' or the 'Company'), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious...
